注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Eledon Pharmaceuticals Inc是一家臨床階段的生物製藥公司。該公司專注於為需要器官或細胞移植、患有自身免疫性疾病及患有肌萎縮側索硬化症(ALS)的人開發靶向藥物。該公司開發中的先導化合物是AT-1501,一種IgG1抗CD40L抗體,對CD40配體(CD40L,也稱為CD154)具有高親和力。與其他抗CD40方法相比,AT-1501旨在提高安全性並提供藥代動力學、藥效學和劑量優勢,阻斷CD40L可抑制CD40和CD11共刺激信號通路,具有更好療效的潛力。該公司從事開發多達四種適應症的AT-1501,包括:ALS、腎臟同種異體移植排斥預防產品、胰島細胞同種異體移植排斥預防產品和IgA腎病(IgAN產品)。該公司已經在志願者和肌萎縮側索硬化症(ALS)患者中完成了Ia/Ib期單次遞增劑量試驗。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Keith A. Katkin | 53 | 2017 | Independent Chairman of the Board |
David-Alexandre C. Gros | 52 | 2020 | CEO & Non Independent Director |
Hamid Djalilian | - | 2018 | Member of Scientific Advisory Board |
Tal Marom | - | 2018 | Member of Scientific Advisory Board |
Seth Pranksy | - | 2018 | Member of Scientific Advisory Board |
John S. McBride | 72 | 2017 | Independent Director |
Michael E. Pichichero | - | 2018 | Member of Scientific Advisory Board |
Anne GM Schilder | - | 2018 | Member of Scientific Advisory Board |
Paola Marchisio | - | 2018 | Member of Scientific Advisory Board |
Steven N. Perrin | 58 | 2020 | President, Chief Scientific Officer & Non Independent Director |
Walter C. Ogier | 67 | 2020 | Independent Director |
Jan L. Hillson | 71 | 2021 | Independent Director |
June H. Lee | 58 | 2020 | Independent Director |
Allan Douglas Kirk | 62 | 2023 | Independent Director |
James A. Robinson | 54 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核